SCHEMBL4896054

SCHEMBL4896054

C[C@@H]1C[C@H](C)CN(C(=O)c2cc(Cl)ccc2NC(=O)CCC(=O)N2CCN(C)CC2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.48
TSHR P16473 3/20 0.46
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
ALDH1A1 P00352 5/20 0.45
NPSR1 Q6W5P4 1/20 0.45
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 3/20 0.44
DRD2 P14416 1/20 0.43
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
MEN1 O00255 2/20 0.42
HPGD P15428 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886969 0.92 SMN1; SMN2 (0.48) LMNASMN1; SMN2MAPTGAATSHR
SCHEMBL4892109 0.89 LMNA (0.45) LMNASMN1; SMN2MAPTGAATSHR
SCHEMBL4896941 0.89 ALDH1A1 (0.47) LMNASMN1; SMN2MAPTGAAALDH1A1
SCHEMBL14087736 0.86 SMN1; SMN2 (0.50) LMNASMN1; SMN2TP53ALDH1A1NPSR1
SCHEMBL4895411 0.83 ALDH1A1 (0.45) LMNASMN1; SMN2TP53ALDH1A1NPSR1
SCHEMBL14103279 0.83 ALDH1A1 (0.41) LMNASMN1; SMN2MAPTGAATSHR
SCHEMBL4894181 0.81 ALDH1A1 (0.46) LMNASMN1; SMN2TSHRTP53ALDH1A1
SCHEMBL4887023 0.81 GABRP (0.51) LMNASMN1; SMN2MAPTGAATP53
SCHEMBL4894751 0.80 POLB (0.43) LMNASMN1; SMN2MAPTGAATSHR
SCHEMBL4892026 0.80 RAB9A (0.49) LMNASMN1; SMN2GAAALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200512-A1 Hepatitis C virus polymerase inhibitors BLANEY JEFFREY MARK 2008-08-21 US disclosed
US-20080200512-A1 Hepatitis C virus polymerase inhibitors BLANEY JEFFREY MARK 2008-08-21 US disclosed
US-20080200512-A1 Hepatitis C virus polymerase inhibitors BLANEY JEFFREY MARK 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200512-A1 Hepatitis C virus polymerase inhibitors SSU72, POLR2H, POLR2E LMNA 3432/4885SMN1; SMN2 4735/4885MAPT 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.